Celgene Signs an Option to License Agreement with Immatics to Develop Novel Adoptive Cell Therapies Targeting Multiple Cancers
Roche and Immatics Collaborate to Evaluate IMA101 + Tecentriq (atezolizumab) for Solid Cancers
Shots:
- Immatics to get $75M up front and is also eligible to receive ~$505M as option exercise fee for each licensed product including development, regulatory & commercial milestone plus royalties on sales. Immatics may develop TCR-T targets for solid tumors based on its XPRESIDENT technology, will take care of development & validation of the programs through lead candidate stage
- Celgene to get exclusive option rights to license Immatics’ three TCR-T targets post lead candidate stage and will take care of WW development, manufacturing and commercialization of therapies. Additionally, Immatics may also have early stage co-development or co-funding rights of the therapies
- Immatics’ XPRESIDENT technology is a used to develop immunotherapies targeting cancer with the identification of novel, highly specific and accurate targets usually present on human leucocyte antigen (HLA) receptors on the surface of tumor cells
Click here to read full press release/ article | Ref: Immatics | Image: Twitter